ArticlePloS one2017
Visceral Fat Area and Serum Adiponectin Level Predict the Development of Metabolic Syndrome in a Community-Based Asymptomatic Population.
Article in PloS one, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Can biomarkers be used to improve diagnosis and prediction of metabolic syndrome in childhood cancer survivors? A systematic review.Obesity reviews : an official journal of the International Association for the Study of Obesity · 2021Pooled it
- Trial
- Visceral Adiposity and Markers of Relative Sarcopenia in Young Adults with Normal Weight Obesity: Gender Differences.Healthcare (Basel, Switzerland) · 2026Article
- Adiponectin and aging: Mechanistic insights, clinical paradox, and therapeutic horizons.Ageing research reviews · 2026Review
- Effect of visceral fat on onset of metabolic syndrome.Scientific reports · 2025Article
- Adiponectin and Adiponectin Receptors in Atherosclerosis.Endocrine reviews · 2025Review
- The Association Between Adiponectin Gene Polymorphism (rs1501299) and Metabolic Syndrome.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Article
- Developing a risk model for early diagnosis of metabolic syndrome in Chinese adults aged 40 years and above based on BMI/HDL-C: a cross-sectional study.BMC endocrine disorders · 2024Article
- Association of rs2241766 and rs1501299 polymorphisms in the adiponectin gene with metabolic syndrome.Immunity, inflammation and disease · 2024Article
- Nutritional status of people who inject drugs in Coastal Kenya: a cross-sectional study.BMC nutrition · 2024Article
- Timing Is Important-Management of Metabolic Syndrome According to the Circadian Rhythm.Biomedicines · 2023Review
- Gender-dependent impact of COVID-19 lockdown on metabolic and psychological aspects.Internal and emergency medicine · 2023Article
- Diet, sleep, and exercise in inflammatory skin diseases.Our dermatology online · 2023Article
- Diminished AdipoR1/APPL1 Interaction Mediates Reduced Cardioprotective Actions of Adiponectin against Myocardial Ischemia/Reperfusion Injury in Type-2 Diabetic Mice.Stem cells international · 2023Article
- Prognostic Potential of the Body Composition Indices in Predicting Positive Changes in Resting Blood Pressure after High-Intensity Interval Training in Adolescents.International journal of environmental research and public health · 2022Article
- The Pathological Links between Adiposity and the Carpal Tunnel Syndrome.Current issues in molecular biology · 2022Review
- From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights.Biomedicines · 2022Review
- Serum milk fat globule-EGF factor 8 protein as a potential biomarker for metabolic syndrome.Clinical and molecular hepatology · 2021Article
- Association of obesity, visceral adiposity, and sarcopenia with an increased risk of metabolic syndrome: A retrospective study.PloS one · 2021Article
- Going Beyond Giving Antiretroviral Therapy: Multimorbidity in Older People Aging with HIV in Nigeria.AIDS research and human retroviruses · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAlthough it has been demonstrated that visceral adipose tissue content and serum levels of adiponectin are associated with metabolic syndrome, their predictive potential for the development of metabolic syndrome remains to be elucidated.
methodsWe studied 1,130 participants of the Seoul Metabolic Syndrome cohort. A total of 337 subjects without metabolic syndrome underwent the follow-up evaluation and finally analyzed. Visceral fat area (VFA) was measured using dual bioelectrical impedance analysis. We compared the 1-year incidence rate of metabolic syndrome among four different groups: Group 1 (high adiponectin level and low VFA), Group 2 (low adiponectin level and low VFA), Group 3 (high adiponectin level and high VFA) and Group 4 (low adiponectin level and high VFA).
resultsMedian follow-up duration was 17 months. Cut-off points of adiponectin level and VFA for metabolic syndrome were 7.34 ng/ml and 84 cm2 for men, and 12.55 and 58 cm2 ng/ml for women, respectively. The incidence of metabolic syndrome was the highest in Group 4 (Group 1; 16.47%, Group 2; 22.08%, Group 3; 25%, and Group 4; 46.15%, p<0.001). Adjusted logistic regression analyses for metabolic syndrome prediction demonstrated that Group 4 exhibited the highest odds ratio compared with Group 1 (4.918 [2.05-11.795]), which was predominantly affected by waist circumference and serum triglyceride levels. Notably, triglyceride/high-density lipoprotein cholesterol (TG/HDL) ratio was significantly higher in Group 4 (p = 0.017).
conclusionIncidence rate of metabolic syndrome was the highest in subjects with low serum adiponectin levels and high visceral fat area. Higher TG/HDL ratio in these subjects suggested insulin resistance may contribute to the development of metabolic syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.